orforglipron – Medxy AI

Long-term Safety of Oral Orforglipron in Japanese Patients with Type 2 Diabetes (ACHIEVE-J): A Multicenter, Randomized, Open-label, Phase 3 Trial

By MedXY 08/18/2026

This phase 3 trial evaluates the 52-week safety of oral orforglipron in Japanese adults with type 2 diabetes, showing an acceptable safety profile when used alongside diet, exercise, and oral antihyperglycemic drugs.

Diabetes & Endocrinology Internal Medicine news

Orforglipron Demonstrates Superior HbA1c Reduction Over Oral Semaglutide in Type 2 Diabetes: Results from the ACHIEVE-3 Trial

By MedXY 03/06/2026

The ACHIEVE-3 phase 3 trial demonstrates that orforglipron, a novel non-peptide oral GLP-1 receptor agonist, provides superior glycemic control compared to oral semaglutide in adults with type 2 diabetes, despite a higher frequency of gastrointestinal adverse events.

Diabetes & Endocrinology news

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

By MedXY 11/28/2025

In ATTAIN‑2, oral orforglipron produced dose‑dependent, statistically superior weight loss and improved HbA1c versus placebo over 72 weeks in adults with overweight/obesity and type 2 diabetes, with an adverse‑event profile dominated by gastrointestinal effects.

Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

By MedXY 09/27/2025

Orforglipron, a novel oral GLP-1 receptor agonist, demonstrated significant and sustained weight reduction in obese adults without diabetes in a 72-week phase 3 trial, with a tolerable safety profile consistent with existing GLP-1 therapies.

Clinical Updates Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY 09/17/2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Clinical Updates Diabetes & Endocrinology news Specialties

Five Oral Obesity Drugs That Could Rival Eli Lilly’s Orforglipron in the Weight Loss Arena

By MedXY 08/17/2025

Eli Lilly's oral GLP-1 drug orforglipron marks a milestone in obesity treatment, yet competition from novel oral therapies by Novo Nordisk, Viking Therapeutics, Roche, Terns Pharmaceuticals, and Rhythm Pharmaceuticals is intensifying, promising diverse mechanisms and potential market shifts.